These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16825413)

  • 1. Detection of hypermutable Escherichia coli strains in a collection of clinical isolates by the fosfomycin-rifampin disk method.
    Carmen Conejo M; Amblar G; Pascual A; Perea EJ; Martínez-Martínez L
    J Clin Microbiol; 2006 Jul; 44(7):2672. PubMed ID: 16825413
    [No Abstract]   [Full Text] [Related]  

  • 2. Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains.
    Galán JC; Tato M; Baquero MR; Turrientes C; Baquero F; Martinez JL
    J Clin Microbiol; 2004 Sep; 42(9):4310-2. PubMed ID: 15365030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.
    Takahata S; Ida T; Hiraishi T; Sakakibara S; Maebashi K; Terada S; Muratani T; Matsumoto T; Nakahama C; Tomono K
    Int J Antimicrob Agents; 2010 Apr; 35(4):333-7. PubMed ID: 20071153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
    Ellington MJ; Livermore DM; Pitt TL; Hall LM; Woodford N
    J Antimicrob Chemother; 2006 Oct; 58(4):848-52. PubMed ID: 16891630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.
    de Cueto M; López L; Hernández JR; Morillo C; Pascual A
    Antimicrob Agents Chemother; 2006 Jan; 50(1):368-70. PubMed ID: 16377714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.
    Netikul T; Leelaporn A; Leelarasmee A; Kiratisin P
    Int J Antimicrob Agents; 2010 Jun; 35(6):609-10. PubMed ID: 20189774
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3.
    Lee SY; Park YJ; Yu JK; Jung S; Kim Y; Jeong SH; Arakawa Y
    J Antimicrob Chemother; 2012 Dec; 67(12):2843-7. PubMed ID: 22893681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics].
    Aykut Arca E; Karabiber N
    Mikrobiyol Bul; 2007 Jan; 41(1):115-9. PubMed ID: 17427560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Detection of Fosfomycin Resistance in Escherichia coli.
    Nordmann P; Poirel L; Mueller L
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates.
    Baquero MR; Nilsson AI; Turrientes Mdel C; Sandvang D; Galán JC; Martínez JL; Frimodt-Møller N; Baquero F; Andersson DI
    J Bacteriol; 2004 Aug; 186(16):5538-42. PubMed ID: 15292159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli.
    Lucas AE; Ito R; Mustapha MM; McElheny CL; Mettus RT; Bowler SL; Kantz SF; Pacey MP; Pasculle AW; Cooper VS; Doi Y
    J Clin Microbiol; 2018 Jan; 56(1):. PubMed ID: 29093108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing glutathione S-transferases.
    Nakamura G; Wachino J; Sato N; Kimura K; Yamada K; Jin W; Shibayama K; Yagi T; Kawamura K; Arakawa Y
    J Clin Microbiol; 2014 Sep; 52(9):3175-9. PubMed ID: 24951800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How is fosfomycin resistance developed in Escherichia coli?
    Cattoir V; Guérin F
    Future Microbiol; 2018 Dec; 13():1693-1696. PubMed ID: 30526061
    [No Abstract]   [Full Text] [Related]  

  • 19. In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.
    Karlowsky JA; Denisuik AJ; Lagacé-Wiens PR; Adam HJ; Baxter MR; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014; 58(2):1252-6. PubMed ID: 24323476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time-kill curve method.
    Quentin C; Saivin S; Lafferriere C; Noury P; Bebear C
    Drugs Exp Clin Res; 1987; 13(4):219-24. PubMed ID: 3476291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.